However, post BCMA-directed CAR T therapy, MM antigen loss is rare, affecting <5% of relapses, possibly because BCMA antigen loss requires a ‘double-hit’ event or since BCMA signalling is essential to plasma cell survival (103, 116, 117). This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.